Clinical Trial Update: PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) [Phase 3]

View source ↗

Summary

A Phase 3 trial (Study P02370) evaluated pegylated interferon alfa-2b (PEG-Intron) plus ribavirin (Rebetol) in chronic hepatitis C patients who did not respond …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis
• Liver Fibrosis

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis, Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2008-12-11